What is Opus Genetics's granted (in shares)?

Opus Genetics (IRD) reported granted (in shares) of 0 in Q1 2026.

What does granted (in shares) mean?

The total number of equity-based instruments, excluding standard stock options, granted to employees or directors during the period. This metric captures the scale of non-option incentive programs, such as restricted stock units or performance shares. It is a key indicator of the company's strategy for talent retention and long-term alignment.

Opus Genetics IRD Granted (in shares)

Granted (in shares) at other companies

Alto Ingredients, Inc.ALTO

1.3M-16.9%

Norwood FinancialNWFL

$23.9K-1.1%

DJT

Trump Media & Technology GroupDJT

0-100%

Cal-Maine FoodsCALM

13.5K—

Southern First BancsharesSFST

65.7K+0.5%

CNB FinancialCCNE

0—

Other financials

Income statement

See full

Revenue$2.2M-50.6%

Operating income-$14.4M-44.7%

Net income-$65.5M-700%

EPS (diluted)-$0.75-213%

Balance sheet

See full

Cash & equivalents$60.0M+43.5%

Total debt$1.2M—

Total equity-$45.8M-1,004%

Total assets$66.8M+38.7%

Cash flow

See full

Operating cash flow-$12.7M-41.5%

Valuation

See full

Market cap$307.14M+442%

Enterprise value$248.38M—

P/S25.6×+21.5×

Profitability

See full

Operating margin-359.1%-68.9pp

Net margin-892.4%-12,322pp

Returns & leverage

See full

Return on equity-449.4%-2,573pp

Debt / equity0.1×—

Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Opus Genetics's granted (in shares)?: Opus Genetics (IRD) reported granted (in shares) of 0 in Q1 2026.
What does granted (in shares) mean?: The total number of equity-based instruments, excluding standard stock options, granted to employees or directors during the period. This metric captures the scale of non-option incentive programs, such as restricted stock units or performance shares. It is a key indicator of the company's strategy for talent retention and long-term alignment.